Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.fr461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Manish Saxena und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction: Hypertension is the most important modifiable risk factor for cardiovascular diseases (CVD), but less than 25% of patients have their blood pressure (BP) under control. The 2025 AHA/ACC Guideline for systolic BP (SBP) targets
Zitieren
APA
Saxena, M., Ferdinand, K. C., Kopjar, B., Novin, M., & Cohen, D. L. (2026). Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr461
Vancouver
Saxena M, Ferdinand KC, Kopjar B, Novin M, Cohen DL. Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr461
BibTeX
@article{Saxena2026,
author = {Saxena, Manish and Ferdinand, Keith C and Kopjar, Branko and Novin, Matthew and Cohen, Debbie L},
title = {Abstract FR461: Blood Pressure Responder Analysis in the Global Launch-HTN Trial of Lorundrostat in Uncontrolled and Resistant Hypertension},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.fr461}
}
EUVIMED